Wang Hui, Zhou Yaxing, Liu Qian, Xu Jiarong, Ma Yuqing
The Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China,
The Department of Anesthesiology, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.
Onco Targets Ther. 2018 Aug 24;11:5171-5181. doi: 10.2147/OTT.S160066. eCollection 2018.
In this study, we evaluated , Cyclin D1, p53, and ki-67 expression immunohistochemically in 117 samples of surgically resected esophageal squamous cell carcinoma (ESCC) and matched normal tumor adjacent tissues and correlated the expression with clinicopathological finding and patient survival. Lymph node metastasis was observed in 36.8% of patients, and organ metastasis was observed in 17.9%. We detected high expression of , Cyclin D1, p53, and ki-67 in 46.1%, 70.1%, 54.7%, and 32.5% of ESCC tissues, respectively. is localized in the tumor cell nuclei, and its expression was significantly associated with N stage (=0.034) and differentiation (=0.003) and ki-67 expression (=0.001), whereas increased Cyclin D1 expression was correlated with high p53 (=0.015). With regard to survival, we found that ESCC patients with high expression had significantly better survival time than those with low expression (=0.021). A multivariate Cox analysis revealed that therapy and high p53 expression and venous invasion were independent predictors of unfavorable prognosis in overall survival (=0.039, =0.004, and =0.023, respectively). Furthermore, higher T stage, clinical stage (pTNM), venous invasion, and high p53 expression were independent predictors of a worse progression-free survival. Notably, co-overexpression of p53 and Cyclin D1 was significantly correlated with poor overall survival and progression-free survival (=0.029 and =0.0227, respectively). Therefore, might be considered as a potential prognostic indicator and a potential target for therapeutic targets in ESCC. p53 staining and combined p53 and Cyclin D1 expression had significantly unfavorable prognostic value for patients with ESCC. These findings provide more insight into ESCC; thus, further investigations into molecular mechanisms of drug resistance are essential.
在本研究中，我们采用免疫组织化学方法评估了117例手术切除的食管鳞状细胞癌（ESCC）样本及其配对的肿瘤旁正常组织中Cyclin D1、p53和ki-67的表达情况，并将这些表达与临床病理特征及患者生存率进行关联分析。36.8%的患者出现淋巴结转移，17.9%的患者出现器官转移。我们分别在46.1%、70.1%、54.7%和32.5%的ESCC组织中检测到Cyclin D1、p53和ki-67的高表达。[此处原文有缺失内容未翻译]定位于肿瘤细胞核，其表达与N分期（P=0.034）、分化程度（P=0.003）及ki-67表达（P=0.001）显著相关，而Cyclin D1表达增加与高p53表达相关（P=0.015）。关于生存率，我们发现高[此处原文有缺失内容未翻译]表达的ESCC患者的生存时间显著长于低[此处原文有缺失内容未翻译]表达的患者（P=0.021）。多因素Cox分析显示，治疗、高p53表达和静脉侵犯是总生存不良预后的独立预测因素（分别为P=0.039、P=0.004和P=0.023）。此外，更高的T分期、临床分期（pTNM）、静脉侵犯和高p53表达是无进展生存更差的独立预测因素。值得注意的是，p53和Cyclin D1的共同过表达与总生存和无进展生存不良显著相关（分别为P=0.029和P=0.0227）。因此，[此处原文有缺失内容未翻译]可能被视为ESCC潜在的预后指标和治疗靶点。p53染色以及p53和Cyclin D1的联合表达对ESCC患者具有显著不良的预后价值。这些发现为ESCC提供了更多见解；因此，进一步研究耐药的分子机制至关重要。
